Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study.
Mamakou V, Hackinger S, Zengini E, Tsompanaki E, Marouli E, Serafetinidis I, Prins B, Karabela A, Glezou E, Southam L, Rayner NW, Kuchenbaecker K, Lamnissou K, Kontaxakis V, Dedoussis G, Gonidakis F, Thanopoulou A, Tentolouris N, Zeggini E.
Mamakou V, et al. Among authors: tsompanaki e.
BMC Psychiatry. 2018 Aug 2;18(1):249. doi: 10.1186/s12888-018-1826-4.
BMC Psychiatry. 2018.
PMID: 30071838
Free PMC article.
Clinical Trial.